FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Heplisav | hepatitis B

Diabetics under 60 should get hep B vaccine

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


In addition to its recommendations about the HPV shot for boys, the CDC's Advisory Committee on Immunization Practices said diabetics under the age of 60 should get the hepatitis B vaccine. Experts voted 12 to 2 in favor of the endorsement after studies showed diabetics were twice as likely to contract the disease versus healthy individuals. The findings did not hold true for those older than 60.

Hep B, which is caused by contact with blood and other bodily fluids, can cause liver damage or cancer if it becomes chronic. Back in 1991, the CDC recommended that children get the vaccine. That recommendation has been extended to other high-risk groups since then. Diabetics are more susceptible to the disease due to the necessity of blood glucose monitoring.

Merck's ($MRK) Recombivax and GlaxoSmithKline's ($GSK) Engerix-B are the only two approved hep B vaccines in the U.S. However, Berkeley, CA-based Dynavax Technologies's promising candidate Heplisav is currently in Phase III clinical trials. Following the CDC panel's announcement this week, Dynavax unveiled data showing Heplisav offers diabetics better protection from hep B than GSK's Engerix-B.

- read the Reuters article
- get more from this GEN story

Related Articles:
HepB vax Heplisav posts positive Ph3 data
Vaccination campaigns beat back viral hepatitis

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Heplisav   hepatitis B